LDL
Lydall, Inc.
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 1.12B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 29.57
- Beta
- 3.09
- Short ratio
- 7.76
- Inst. own
- 98.97%
- Dividend
- 0.00
- Ex-div date
- Feb 26, 1984
- Earnings
- Oct 26, 2021
- 50-d avg
- 61.97
- 200-d avg
- 49.53
- 1y target
- 62.10
Key statistics
- Market cap
- 1.12B
- Enterprise value
- 1.30B
- Trailing P/E
- 0.00
- Forward P/E
- 29.57
- PEG ratio
- 1.93
- Price / sales
- 1.29
- Price / book
- 4.07
- EPS (TTM)
- -0.033
- Beta
- 3.09
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -0.07%
- Revenue (TTM)
- 866.20M
- Revenue growth
- 51.70%
- Free cash flow
- 48.97M
- Total cash
- 102.54M
- Total debt
- 284.49M
- Return on equity
- -0.22%
- Shares outstanding
- 18.04M
- Short % of float
- 6.51%
- 50-day average
- 61.97
- 200-day average
- 49.53
Analyst view
Consensus: hold
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 26, 2021
Expected Oct 26, 2021. Consensus EPS estimate 0.48.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 26, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
| Jul 28, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| Apr 27, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
| Feb 23, 2021 | Dec 1, 2020 | 0.00 | — | — | — |
| Oct 27, 2020 | Sep 1, 2020 | 0.00 | — | — | — |
| Jul 28, 2020 | Jun 1, 2020 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2020 | Sidoti & Co. | main | — | Buy |
| May 12, 2020 | Sidoti & Co. | main | — | Buy |
| Mar 10, 2020 | Sidoti & Co. | up | Neutral | Buy |
| Oct 30, 2019 | Sidoti & Co. | down | Buy | Neutral |
| Feb 26, 2019 | Sidoti & Co. | main | Buy | Buy |
| Sep 13, 2017 | Sidoti & Co. | up | Neutral | Buy |
About Lydall, Inc.
Lydall, Inc. designs, manufactures, and markets specialty engineered filtration media, industrial thermal insulating solutions, and automotive thermal and acoustical barriers for filtration/separation and thermal/acoustical applications worldwide. It operates through Performance Materials, Technical Nonwovens, and Thermal Acoustical Solutions segments. The Performance Materials segment offers filtration media solutions for air, fluid power, life science and industrial applications, gasket and sealing solutions, thermal insulation, energy storage, and other engineered products. This segment also nonwoven veils, papers, and advanced composite solutions comprising thermal insulation papers and insulation media for high temperature technology applications; and life sciences filtration products for biopharmaceutical diagnostic and analytical testing, potable water filtration, and high purity process filtration in food, beverage, and medical applications. The Technical Nonwovens segment offers nonwoven rolled-good felt media and filter bags used primarily in industrial air and liquid filtration applications. The Thermal Acoustical Solutions segment offers engineered products for transportation sector to thermally shield sensitive components from high heat, improve exhaust gas treatment, and lower harmful emissions, as well as assist in the reduction of noise, vibration, and harshness. Its products are used in the interior, underbody, and underhood of cars, trucks, SUVs, heavy duty trucks, and recreational vehicles. The company markets its products to original equipment manufacturers, Tier 1, Tier 2, and Tier 3 industrial customers. Lydall, Inc. was founded in 1879 and is headquartered in Manchester, Connecticut.
- Sector
- Industrials
- Industry
- Specialty Industrial Machinery
- Country
- United States
- Website
- lydall.com
News
- Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
- CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
- NewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering Pill
- Merck's LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
- Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
- Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
- NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today
Your note
Sign in to keep a note on LDL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BILLS DAVID G | Director | Stock Award(Grant) | Apr 18, 2021 | 23,363 |
| BURDETT KATHLEEN | Director | Stock Award(Grant) | Apr 18, 2021 | 28,345 |
| CANNON JAMES J | Director | Stock Award(Grant) | Apr 18, 2021 | 14,578 |
| FARRELL MATTHEW T | Director | Stock Award(Grant) | Apr 18, 2021 | 79,171 |
| GILES MARC T | Director | Stock Award(Grant) | Apr 18, 2021 | 34,557 |
| GRAVES PAUL W | Director | Stock Award(Grant) | Apr 19, 2021 | 773 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 14.73% | 2,656,308 | 160.76M | Jun 29, 2021 |
| Dimensional Fund Advisors LP | 6.50% | 1,171,889 | 70.92M | Jun 29, 2021 |
| Vanguard Group, Inc. (The) | 6.05% | 1,090,628 | 66.00M | Jun 29, 2021 |
| Magnetar Financial LLC | 5.86% | 1,056,318 | 63.93M | Jun 29, 2021 |
| Neuberger Berman Group, LLC | 5.15% | 928,950 | 56.22M | Jun 29, 2021 |
| Versor Investments, LP | 4.63% | 835,643 | 50.57M | Jun 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | 6.34% | 1,143,154 | 70.85M | Aug 30, 2021 |
| Vanguard Total Stock Market Index Fund | 2.70% | 487,783 | 29.52M | Jun 29, 2021 |
| iShares Russell 2000 ETF | 2.26% | 407,891 | 25.28M | Aug 30, 2021 |
| Vanguard Extended Market Index Fund | 1.41% | 253,579 | 15.35M | Jun 29, 2021 |
| DFA U.S. Small Cap Value Series | 1.38% | 249,641 | 15.28M | Jul 30, 2021 |
| DFA U.S. Micro Cap Series | 1.02% | 184,878 | 11.31M | Jul 30, 2021 |